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PSY9  
A NETWORK META-ANALYSIS OF RANDOMIZED, CONTROLLED TRIALS OF 
USTEKINUMAB AND ADALIMUMAB FOR MODERATE-TO-SEVERE  
PSORIASIS  
Odom D1, Brogan A1, Talbird SE1, Schenkel B2 
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Janssen Scientific Affairs, LLC, 
Horsham, PA, USA  
OBJECTIVES: Psoriasis is a chronic, immune-mediated, inflammatory skin 
disease that negatively impacts patients’ health-related quality-of-life. Biologic 
medications have been developed and approved for the condition in recent years 
that have greatly improved patients’ care; however, little is known about their 
comparative efficacy. Our research objective was to synthesize and compare the 
efficacy of two of these new biologic treatments, ustekinumab and adalimumab. 
METHODS: A literature review was conducted of randomized, controlled trials 
investigating the efficacy of ustekinumab (45 mg or 90 mg) and adalimumab 
(40mg) according to their approved FDA labels. As no head-to-head trials existed 
at the time of the study, a Bayesian network meta-analysis allowing for indirect 
comparisons was conducted on the ordered probit scale to evaluate comparative 
efficacy at a common week-12 time point based on the Psoriasis Area and 
Severity Index (PASI) 50, 75, 90, and 100 and the Physician’s Global Assessment 
(PGA) 0/1. The primary analysis was based on the intent-to-treat populations, 
and sensitivity analysis was conducted using the ustekinumab dose appropriate 
for patients’ body weight per the product label. RESULTS: Seven clinical trials 
representing over 4,000 patients were included in the meta-analysis. The meta-
analysis showed that PASI 50, 75, 90, and 100 response rates at week 12 were 
76%, 55%, 29%, and 10% for adalimumab; 89%, 73%, 47%, and 20% for 
ustekinumab 45 mg; and 91%, 76%, 51%, and 24% for ustekinumab 90 mg, 
respectively. PGA 0/1 response rates at week 12 were 58%, 64%, and 69% for 
adalimumab, ustekinumab 45 mg, and ustekinumab 90 mg, respectively. Weight-
based sensitivity analysis showed similar results between adalimumab and 
ustekinumab but higher efficacy for ustekinumab 45 mg in pts ≤100kg compared 
with ustekinumab 90 mg in pts >100kg per the label. CONCLUSIONS: This 
network meta-analysis provides additional information about the comparative 
effectiveness of ustekinumab and adalimumab in treatment of moderate-to-
severe PsO.  
 
PSY10  
TREATMENT OF PERIPHERAL NEUROPATHIC PAIN WITH THE CAPSAICIN 8% 
PATCH: AN OBSERVATIONAL, REAL-WORLD STUDY IN SIX EUROPEAN 
COUNTRIES  
Poole CD1, Chambers C2, Odeyemi II2, Currie CJ1 
1Cardiff University, Cardiff, UK, 2Astellas Pharma Europe Ltd., Chertsey, UK  
OBJECTIVES: The capsaicin 8% patch (QUTENZATM) is licensed for the treatment 
of peripheral neuropathic pain in non-diabetic adults. The purpose of  
this observational study was to determine if levels of effectiveness observed  
in clinical trials are translated into routine clinical practice, and to determine 
how this novel treatment is being used more generally by practicing physicians 
so that real-world cost effectiveness can be determined. METHODS: This 
observational study of routine practice (ASCEND) is being carried out using an 
online, electronic data capture platform for the case report forms that includes 
translation into multiple languages. Following treatment, at least 12 months’ 
follow-up is planned for each patient in this ongoing study. Demographic, 
clinical, process and patient-reported outcome parameters are reported. Pain is 
evaluated using the Numeric Pain Rating Scale (NPRS). RESULTS: A total of 166 
patients from 31 hospital sites in six European countries have been enrolled  
and treated with capsaicin 8% patch. Of these 59% are female with an  
overall mean age of 58.7 (sd 14.5) years. The reported indications include post-
operative and/or post-traumatic neuropathic pain (n 67; 43.2%) and post-herpetic 
neuralgia (31; 20.0%). Baseline mean pain score was 6.57 (sd 1.98) units.  
Pain improved by an average of 1.8 and 2.3 units on the NPRS at weeks two and 
eight, respectively (paired samples comparison p<0.001 at both time points). A 
total of 56% of enumerable subjects (N=100) were classified as responders to 
treatment (≥30% improvement in pain at the Week 8 assessment). On average, 
1.5 (sem 0.06) patches were used per treatment. CONCLUSIONS: When used in 
routine clinical practice, the degree of pain relief evident when using the 
capsaicin 8% patch was greater than the levels seen in randomised trials. 
Interestingly, this was achieved with a reduced number of patches, suggesting 
current cost-effectiveness estimates based on clinical trial data may be 
conservative.  
 
PSY12  
META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS OF THYROIDECTOMY 
WITH ULTRASONIC SCALPAL VERSUS CONVENTIONAL SURGERY  
Li H1, Xu D2 
1China Pharmaceutical University, Nanjing, Jiangsu, China, 2Johnson & Johnson Medical China, 
Beijing, China  
OBJECTIVES: Undertake a meta-analysis of all randomized controlled trials 
(performed in China and other Countries) comparing effective and safety of 
ultrasonic scalpel (UAS) with conventional surgery for thyroidectomy. 
METHODS: A comprehensive search for published RCTs published in major 
medical database (PubMed, Embase, Elsevier, Wanfang and CNKI) was performed 
from January 2003 to November 2012; Reviews of each study were conducted and 
data were extracted.Outcome measures analyzed included operation time, 
intraoperative blood loss, overall drainage volume, length of stay and post-
operative complication rates. RESULTS: Data were retrieved from 26 RCTs(16 
from China, 10 from other countries) describing 3011 patients In most cases 
conventional vessel ligation and tight were used as a conventional method. The 
results of the meta-analysis demonstrated significant improvement of 
perioperative outcomes with the use of UAS instead of conventional surgical 
instrumentation. Operative time was significantly reduced from a mean of 84.6 
min to 61.7(WMD: -21.66 minutes; 95% CI: -22.61, -20.71) intraoperative blood loss 
was decreased from a mean of 61.4 ml to 31.6 ml (WMD: -23.58 mL; 95% CI: -
24.33,-22.83),length of stay was shorten from a mean of 5.8 to 4.8 days (WMD: -
0.8 day; 95% CI: -0.86, -0.72) , overall drainage volume was reduced from a mean 
of 56.9 ml to 37.4(WMD: -21.28 mL; 95% CI: -22.15, -20.41) in the patients 
underwent thyroidectomy with UAS. It also showed that the patients who were 
treated with UAS presented more favorable results in incidence of post-operative 
complications (OR: 0.54, 95% CI: 0.36, 0.81). CONCLUSIONS: Ultrasonic scalpel 
showed significant advantages over conventional methods in the thyroidectomy, 
including shortened operation time, shortened length of stay, reduced 
intraoperative blood loss and shortened overall drainage volume. Besides, it can 
also decrease the post-operative complication risks.  
 
PSY13  
EFFECTS OF PHENTERMINE AND TOPIRAMATE EXTENDED-RELEASE (PHEN/TPM 
ER) TREATMENT ON WEIGHT LOSS (WL) WHEN STRATIFIED BY BASELINE 
BODY MASS INDEX (BMI) OVER 1 YEAR  
Ryan D1, Church T2, Karnawat S3, Troupin B3 
1Pennington Biomedical Research Center, Baton Rouge, LA, USA, 2Biomedical Research Center, 
Baton Rouge, LA, USA, 3VIVUS, Inc., Mountain View, CA, USA  
OBJECTIVES: The 1998 NHLBI Obesity Guidelines state “extremely obese persons 
often do not benefit from more conservative treatments for WL.” This post-hoc 
analysis explores the use of PHEN/TPM ER, a pharmacologic adjunct to lifestyle 
modifications, to impact WL across BMI ranges, including extreme obesity. 
METHODS: Data from two double-blind, placebo-controlled Phase 3 studies 
(CONQUER [BMI ≥27 to ≤45kg/m2], EQUIP [BMI ≥35kg/m2]) were pooled and 
subjects stratified by baseline BMI (kg/m2; <30, ≥30-<35, ≥35-<40, ≥40-<45, ≥45) 
and by randomized dose over 56 weeks (ITT-LOCF). Subjects were randomized to 
placebo (n=1477), PHEN 3.75mg/TPM ER 23mg (3.75/23; n=234), PHEN 7.5mg/TPM 
ER 46mg (7.5/46; n=488), or PHEN 15mg/TPM ER 92mg (15/92; n=1479). All subjects 
received the same lifestyle intervention. RESULTS: At baseline, mean weight was 
107.4 kg and mean BMI was 38.4 kg/m2. At week 56, least-squares mean percent 
WL was -1.5%, -4.7%, -8.2%, and -10.4% for placebo, 3.75/23, 7.5/46, and 15/92, 
respectively (P<.0001 versus placebo). Similar dose trends were seen when 
subjects were stratified by baseline BMI for placebo, 3.75/23, 7.5/46, and 15/92, 
respectively: BMI <30, -1.1%, dose not included in CONQUER, -9.1%, and -9.1%; 
BMI ≥30-<35, -1.8%, -10.3%, -8.0%, and -10.4%; BMI ≥35-<40, -1.8%, -5.5%, -8.8%, 
and -10.2%; BMI ≥40-<45, -1.9%, -4.4%, -8.3%, and -11.5%; and BMI ≥45, -1.3%,  
-5.5%, -8.8%, and -11.0% (P<0.005 versus placebo, all comparisons with 7.5/46 and 
15/92). Similar WL trends were observed with mean absolute WL (P<0.005 versus 
placebo, all comparisons with 7.5/46 and 15/92). Common adverse events were 
constipation, dry mouth, and paraesthesia. CONCLUSIONS: PHEN/TPM ER was 
associated with significant WL versus placebo across all BMI categories, with 
dose proportional percent WL increases across BMI categories within each 
treatment arm. We conclude that significant WL is possible across a wide range 
of BMIs, including extreme obesity, with PHEN/TPM ER use.  
 
PSY14  
OBSERVATIONAL STUDY OF FERRIC CARBOXYMALTOSE (FCM) IN FRANCE 
(ONCOFER STUDY; INTERIM ANALYSIS)  
Toledano A1, Luporsi E2, Morere JF3, Scotté F4, Huot-Marchand P5, Zakin L6, Mahi L7,  
Bugat R8 
1American hospital of Paris, neuilly sur seine, France, 2Centre Alexis Vautrin, Vandoeuvre Les 
Nancy , Meurthe et Mosel, France, 3Hôpital Avicenne, Bobigny, France, 4Hôpital Européen George 
Pompidou, Paris, Ile de France, France, 5ICTA, fontaine les dijon, France, 6Vifor Pharma 
International, Neuilly-sur-Seine Cedex, Ile de France, France, 7Vifor Pharma International, 
Neuilly-sur-Seine Cedex, France, 8Institut Claudius Regaud, Toulouse, France  
OBJECTIVES: This French multicenter observational study aims to describe 
clinical practice Ferric carboxymaltose (FCM) use in patients with hematological 
malignancies or solid tumors. METHODS: Two cohorts of patients (1:1)  
are enrolled. Cohort 1 (retrospective): patients treated in 2010 with any 
intravenous iron (IV) or red blood cell transfusion if no IV iron; Cohort 2 
(prospective): patients treated with FCM after July 1st 2011. Patient 
characteristics were collected for a period of 3 months pre and post intervention. 
Outcomes of the first 100 patients are described below. RESULTS: Fifty patients 
were analyzed in each cohort (mean age, 62 and 66 y.; solid tumors, 84% and 
100%; metastatic, 61% and 63% for Cohorts 1 and 2, respectively). In Cohort 1, 16 
patients received intravenous iron (iron sucrose (IS)) and 34 were transfused. The 
mean total iron dose was 706 mg for IS in cohort 1 and 960 mg for FCM in cohort 
2; the mean number of infusions was 3.8 and 1.8 for IS and FCM respectively. In 
cohort 2, 69% of the administrations were done at home. In patients receiving 
FCM without erythropoietin stimulating agents (ESA), mean Hb (g/dL) increased 
from 10.9 to 12.1, from baseline to Month 3. ESA use was 44% in cohort 1 vs 22% 
in cohort 2 during observational period. No serious adverse events related to IS 
or FCM were observed. CONCLUSIONS: FCM was well tolerated and effective in 
treating iron deficiency anemia. FCM was mostly given at home with fewer 
infusions required compared to IS. Interim results to be confirmed by the final 
analysis.  
 
PSY15  
META-ANALYSIS FOR EFFICACY OF ROMIPLOSTIM FOR TREATMENT OF 
IMMUNE IDIOPATHIC THROMBOCYTOPENIA  
Aggarwal S, Topaloglu H, Messenger M 
Novel Health Strategies, Bethesda, MD, USA  
OBJECTIVES: Immune (idiopathic) thrombocytopenia (ITP) is an autoimmune 
condition characterized by increased platelet destruction and suboptimal 
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platelet production, resulting in low platelet counts (thrombocytopenia). 
Romiplostim has shown efficacy in increasing platelet counts. The objective  
of this study was to conduct meta-analysis and present total evidence  
for Romiplostim for treatment of ITP. METHODS: For this meta-analysis we 
included randomized controlled trials (RCTs) evaluating Romiplostim for the 
treatment of ITP. We included RCTs that compared romiplostim versus placebo 
for management of ITP, had a treatment duration of at least 24 weeks,  
were doubleblind (patients and investigators blinded) and reported data  
on platelet response. A systematic literature search for Etanercept trials  
was undertaken for the databases Pubmed, Embase, Biosis, Google Scholar,  
and Cochrane. Data was collected for the study size, interventions, year, and the 
two outcomes overall and durable platelet response rate. For meta-analysis, 
random effects and fixed effects models were used to obtain cumulative 
statistics. RESULTS: Two RCTs with a total of 125 patients were identified.  
The pooled response rates for Romiplostim for overall platelet response  
rate were 82% (95% CI 73%-90%); and for durable platelet response rate were 48% 
(95% CI 26%-71%). The pooled response rates for placebo for overall platelet 
response rate were 7% (95% CI 0%-15%), and for durable platelet response rate 
were 2% (95% CI 0%-4%). For overall platelet response rate the cumulative 
relative risk with Romiplostim versus placebo was 0.09 (95% CI 4%-14%). For 
durable platelet response rate, the cumulative relative risk with Romiplostim 
versus placebo was 0.03 (95% CI 0%-6%). CONCLUSIONS: Meta-analysis shows 
Romiplostim offers patients with ITP an effective therapeutic option for 
increasing platelet counts.  
 
PSY16  
PHARMACOECONOMICAL EVALUATION OF RITUXIMAB FOR NON-HODGKIN'S 
LYMPHOMA: A SYSTEMATIC REVIEW  
SUN Y 
Peking University, Beijing, China  
OBJECTIVES: Rituximab maintenance therapy is associated with significant 
improvement in progression-free and overall survival in patients with NHL. 
However, treatment with rituximab causes considerable costs for health care 
systems. This article provides an overview of Pharmacoeconomical evaluations 
of rituximab and appraises their methodological quality. METHODS: A 
systematic literature search of cost-effectiveness studies on rituximab was 
carried out in several databases, such as PubMed, HTA databases and so on. 
Based on specified inclusion and exclusion criteria, cost-effectiveness studies 
were identified that compared standard chemotherapy with standard 
chemotherapy plus rituximab in patients with a subtype of NHL, including 
diffuse large B-cell lymphoma. The methodological quality of the studies was 
assessed using a quality checklist. RESULTS: The included researches are from 
several countries: the US, UK, Finland, France, Italy and so on. The average ICER 
in the UK is about USD$16318/QALY (GBP10173/QALY), $17688/QALY 
(EUR13275/QALY) in the EU and USD$22461/QALY in the US. All economic 
evaluations reported incremental cost-effectiveness ratios (ICERs) for the add-on 
therapy with rituximab that were below the country-specific thresholds, 
GBP20000~30000/QALY in the UK, EUR30000 ~50000/QALY in the EU and 
USD100000/QALY in the US. CONCLUSIONS: Although the cost of rituximab-
related treatments are relatively higher, they are still cost-effective therapy 
based on the country-specific thresholds.  
 
PSY17  
SYSTEMATIC REVIEW OF PHARMACOLOGIC THERAPIES FOR NEUROPATHIC 
PAIN ASSOCIATED WITH STROKE, HIV, TRAUMA, AND MULTIPLE  
SCLEROSIS  
Sudharshan L1, Snedecor SJ1, Cappelleri JC2, Sadosky A2, Desai P3, Jalundhwala Y4, 
Botteman M1 
1Pharmerit International, Bethesda, MD, USA, 2Pfizer Inc., New York, NY, USA, 3The University 
of Texas, Austin, TX, USA, 4University of Illinois at Chicago, Chicago, IL, USA  
OBJECTIVES: To conduct a systematic review and comparison of pharmacologic 
therapies for treating neuropathic pain (NeP) associated with stroke, HIV, 
trauma, and multiple sclerosis (MS). METHODS: Systematic searches of 
electronic literature databases were conducted to identify randomized, blinded, 
controlled trials of NeP associated with stroke, HIV, trauma, and MS published 
through June 2011. Identified references were screened for inclusion by two 
independent reviewers. Data extracted and evaluated from each study included 
pain severity (11-point numeric rating scale [NRS] or visual analog scale [VAS]), 
proportion of patients achieving 30% and 50% reductions in pain, adverse events 
(AEs), and discontinuations. RESULTS: Eighteen studies met inclusion/exclusion 
criteria. Sample sizes were generally small (11-145 patients) except for 2 HIV, 1 
trauma, and 1 post-stroke pain containing 219-307 patients. Two of the four 
stroke studies presenting mean treatment effects over that of placebo reported 
reductions of -0.2 to -0.3 on NRS for pregabalin, amitriptyline and 
carbamazepine. Of the nine HIV studies, topical capsaicin gave the largest 
treatment effect on the NRS (-2.5). NGX-4010 was the only treatment showing 
higher relative benefit for 30% or 50% pain reduction compared with placebo. Of 
three trauma studies, pregabalin, mexiletine, and gabapentin showed NRS or 
VAS mean pain reductions numerically superior to placebo, although some 
effects were very small. Only pregabalin provided a significant relative benefit of 
30% pain reduction. Two MS studies (<30 patients each) showed mixed efficacy 
for lamotrigine (+0.8 NRS) and levetiracetam (-33.1 VAS). Most studies had 
insufficient data to compare AE risk. Available discontinuation data showed 
similar rates between treatments and placebo. CONCLUSIONS: Studies of NeP 
treatment associated with stroke, HIV, trauma, and MS were few, frequently 
small, and lacked measurements of uncertainty necessary to perform adequate 
comparisons. More and better evaluation of NeP treatment in patients with these 
conditions are needed.  
PSY18  
SYSTEMATIC LITERATURE REVIEW AND META-ANALYSIS OF B-CELL 
THERAPIES IN SYSTEMIC LUPUS ERYTHEMATOSUS  
Denno MS, Dandappanavar AS, Raju AD, Clark RS, Campbell CM, Regan TS, Jackson JH, 
Skodny PF 
Xcenda, LLC, Palm Harbor, FL, USA  
OBJECTIVES: Systemic lupus erythematosus (SLE) is a chronic connective tissue 
disorder in which the immune system attacks healthy tissue and cells, leading to 
symptoms such as fatigue, muscle pain, and a “butterfly” rash on the nose and 
cheeks. The study objective was to conduct a systematic review and meta-
analysis of new and pipeline B-cell therapies for SLE treatment. METHODS: A 
systematic literature review was conducted in MEDLINE databases from January 
1, 2007 to December 26, 2012 that evaluated primary literature of phase 2 or 
phase 3 studies of B-cell therapies (belimumab, atacicept, epratuzumab, 
tabalumab, blisibimod) in SLE. The search was limited to human studies 
published in English. Descriptive and outcomes data were extracted to assess the 
feasibility of conducting a meta-analysis of comparable endpoints among the 
selected studies. Meta-analysis is in progress. RESULTS: Based on 90 articles 
returned from search terms, 6 articles met search criteria. The 84 excluded 
articles comprised: 29 review articles, 11 phase 1 trials, 14 non-SLE disease 
states, 6 non-human trials, and 24 biologic components of B-cell inhibition. Final 
search results provided 2 studies of pooled analyses of phase 3 belimumab trials. 
Two studies were randomized phase 3 trials of belimumab and 2 studies were 
randomized phase 2 trials of belimumab. The remaining 2 studies were pooled 
sub-analyses of the aforementioned phase 3 trials. Using the criteria set forth by 
Jadad, et al, 4 articles were graded to be excellent (≥66% criteria met), and 2 
articles were rated as poor (<66% criteria met). Feasibility analyses resulted in 2 
studies wherein a meta-analysis could be conducted for SRI response rate, PGA 
score, SF-36 score, and steroid-sparing activity of belimumab vs placebo. 
CONCLUSIONS: Current published literature of phase 2 and phase 3 trials in  
B-cell new product entrants is limited to belimumab for the treatment of SLE.  
 
PSY19  
TRENDS IN OBESITY AWARENESS, WEIGHT CONTROL AND WEIGHT CONTROL 
PRACTICES AMONG OBESE ADULTS IN THE UNITED STATES, 1999-2010  
Yuan J, Lu K 
South Carolina College of Pharmacy – USC Campus, Columbia, SC, USA  
OBJECTIVES: To examine trends in weight control and weight control practices 
among obese persons aged 20 years and older in the U.S from 1999-2010. 
METHODS: Data were analyzed from National Health and Nutrition Examination 
Survey (NHANES) 1999-2010, representing the civilian, noninstitutionalized 
population of the U.S. Obesity was defined as a BMI greater than 30 kg/m2. 
Weight control and weight control practices were based on self-report. All survey 
periods were age-adjusted to the year 2000 US population. RESULTS: Obesity 
awareness decreased from 92.0% (95% CI, 89.9-94.1%) in 1999-2000 to 90.3% (95% 
CI, 89.0-91.6%) in 2009-2010 (P<0.001), it remained stable among men, but 
decreased significantly among women (P=0.01). The percentage of obese persons 
tried to control their weight in the previous 12 months remained stable over 
time, across age, race, and sex groups, including those who tried to lose weight 
(58.6% in 1999-2000 vs. 59.2% in 2009-2010) and those who tried to maintain 
weight (9.1% in 1999-2000 vs. 8.8% in 2009-2010). Among obese persons who tried 
to control their weight, proportion of those who changed their dietary habit 
increased from 48.7% (95%CI, 43.9-53.5%) in 1999-2000 to 63.3% (95%CI, 59.2-
67.4%) in 2009-2010 (P<0.001), proportion of those who increased physical 
activities level increased from 32.6% (95%CI, 28.6-36.6%) in 1999-2000 to 39.3% 
(95%CI, 35.4-43.1%) in 2009-2010 (P=0.05), but proportion of those who combined 
diet control with the higher levels of physical activity did not change 
significantly over time (27.0% in 1999-2000 vs. 33.7% in 2009-2010; P=0.32). 
CONCLUSIONS: Although sixty-eight percent of obese adults reported pursuing 
weight control in NHANES 2009-2010, most of them did not follow 
recommendations for combined caloric restriction with higher levels of physical 
activity.  
 
PSY20  
PREVALENCE OF COMMERCIALLY INSURED ACUPUNCTURE AND 
CHIROPRACTIC USE AMONG PATIENTS WITH CHRONIC INFLAMMATION OR 
PAIN DIAGNOSES  
Bonafede MM 
Truven Health Analytics, Cambridge, MA, USA  
OBJECTIVES: To describe the prevalence of acupuncture and chiropractic use 
among commercially insured patients with rheumatoid arthritis, osteoarthritis, 
neuropathic pain, diabetic peripheral neuropathy or general joint or back pain. 
METHODS: Patients who used acupuncture or chiropractic during 2009-2011 
were identified in the Truven Health Analytics MartketScan Commercial Claims 
and Encounters and Medicare Supplemental Databases. The disease subgroups 
were identified using ICD-9-CM codes. All analyses were conducted using the 
Truven Health Treatment Pathways research tool. RESULTS: Overall, less than 
one-half percent of patients in the MarketScan Research Databases had an 
acupuncture claim between 2009 and 2011. The average age of an acupuncture 
user was 45.2 (SD=14.3) and more than two-thirds (67.7%) were female. 
Acupuncture use was highest among patients with neuropathic pain (1.41%), 
followed by general joint or back pain (1.23%), osteoarthritis (1.10%), rheumatoid 
arthritis (0.99%), and diabetic peripheral neuropathy (0.65%). By comparison, 
7.1% of patients in the dataset had a chiropractic claim between 2009 and 2011. 
Chiropractic users had an average age of 41.9 (SD=16.5) and 56.7% were female. 
Chiropractic use was most prevalent among patients with general joint or back 
pain (21.0%), followed by neuropathic pain (17.4%), osteoarthritis (13.7%), 
rheumatoid arthritis (10.9%), and diabetic peripheral neuropathy (9.7%). 
